Oteseconazole Drug Asset Due Diligence Report 2026

This Oteseconazole Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Oteseconazole can convert its Small molecule drug profile and fungal CYP51A1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Oteseconazole (query alias: Oteseconazole)
Modality / target	Small molecule drug; fungal CYP51A1; fungal CYP51A1 inhibitors
Highest global status	Approved
Originator	Mycovia Pharmaceuticals, Inc.
Active developers	Evenus Pharmaceutical Laboratories, Inc., Mycovia Pharmaceuticals, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd.

The MCP disease footprint includes Candidiasis, Vulvovaginal, Meningitis, Cryptococcal, Onychomycosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05074602	Phase 3	Recruiting	196	The proportion of subjects with one or more culture-verified VVC episodes during the study.
NCT06666322	Phase 2/3	Recruiting	2000	Rate of cerebrospinal fluid (CSF) Cryptococcus clearance (Early Fungicidal Activity, or EFA)
NCT07044947	Not Applicable	Not yet recruiting	3000	The proportion of subjects achieving clinical cure at 6-month,

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial

Phase 3; n=321; evaluation: Superior. Reported fields: Therapeutic cure rate(28-day) = 45.91 % ; Therapeutic cure rate(28-day) = 66.88 %

Mycovia Pharmaceuticals Announces Presentation of Topline Results from Two Studies Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC) at the 2022 IDSOG Annual Meeting

Phase 3; n=71; evaluation: Positive. Reported fields: No recurrence(96-week) = 85 %

Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis

Phase 3; n=not disclosed; evaluation: Positive. Reported fields: Adverse Event: adverse events = adverse events were similar in both treatment groups ; Adverse Event: adverse events = adverse events were similar in both treatment groups

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Oteseconazole addresses Candidiasis, Vulvovaginal, Meningitis, Cryptococcal, Onychomycosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-10-16	Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Candidiasis	Phase 3	Financial terms not disclosed
2019-06-17	江苏恒瑞医药股份有限公司关于引进美国Mycovia公司产品的公告	Phase 3	US$101.0M milestones
2018-01-01	Malin's Priority Asset, Viamet Pharmaceuticals ("Viamet"), has an economic interest, recently announced a strategic partnership with Gedeon Richter plc.	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Dosing regimen for oteseconazole”. The milestone feed surfaced a patent-application signal described as “Compositions comprising oteseconazole”. The milestone feed surfaced a patent-application signal described as “Solid state forms of oteseconazole and process for preparation thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO